The article "Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview" by Xu Liu et al. reviews the advancements in drug delivery systems (DDS) for cancer immunotherapy. The authors highlight the limitations of traditional immunotherapy, such as systemic injection leading to off-target effects and immune-related adverse reactions. To address these issues, they discuss the development and application of various DDS, including nanoparticles and coupling technologies. Nanoparticles, such as liposomes, polymer nanoparticles, and inorganic nanoparticles, are widely used for drug delivery due to their ability to improve drug solubility, targeting, and pharmacokinetics. The article details the use of nanoparticles for activating dendritic cells (DCs), delivering STING agonists, and promoting the polarization of tumor-associated macrophages (TAMs). For example, liposome-based nanoparticles have been shown to enhance the activation of DCs and improve antitumor immune responses. Additionally, extracellular vesicles (EVs) are discussed as promising carriers for DC vaccines, with studies demonstrating their effectiveness in enhancing immune responses and tumor growth inhibition. Coupling technologies, such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), are also explored. ADCs combine monoclonal antibodies with cytotoxic drugs, while PDCs use peptides for targeted delivery. The article reviews the mechanisms and clinical applications of these technologies, including their potential to reduce systemic toxicity and enhance the efficacy of immunotherapy. Despite the promising results, the authors acknowledge the challenges in translating these DDS from preclinical to clinical settings, such as differences between animal models and human studies, disease heterogeneity, and the need for standardized production methods. Overall, the article provides a comprehensive overview of the current state and future directions of DDS in cancer immunotherapy, emphasizing the potential of these technologies to improve treatment outcomes.The article "Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview" by Xu Liu et al. reviews the advancements in drug delivery systems (DDS) for cancer immunotherapy. The authors highlight the limitations of traditional immunotherapy, such as systemic injection leading to off-target effects and immune-related adverse reactions. To address these issues, they discuss the development and application of various DDS, including nanoparticles and coupling technologies. Nanoparticles, such as liposomes, polymer nanoparticles, and inorganic nanoparticles, are widely used for drug delivery due to their ability to improve drug solubility, targeting, and pharmacokinetics. The article details the use of nanoparticles for activating dendritic cells (DCs), delivering STING agonists, and promoting the polarization of tumor-associated macrophages (TAMs). For example, liposome-based nanoparticles have been shown to enhance the activation of DCs and improve antitumor immune responses. Additionally, extracellular vesicles (EVs) are discussed as promising carriers for DC vaccines, with studies demonstrating their effectiveness in enhancing immune responses and tumor growth inhibition. Coupling technologies, such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), are also explored. ADCs combine monoclonal antibodies with cytotoxic drugs, while PDCs use peptides for targeted delivery. The article reviews the mechanisms and clinical applications of these technologies, including their potential to reduce systemic toxicity and enhance the efficacy of immunotherapy. Despite the promising results, the authors acknowledge the challenges in translating these DDS from preclinical to clinical settings, such as differences between animal models and human studies, disease heterogeneity, and the need for standardized production methods. Overall, the article provides a comprehensive overview of the current state and future directions of DDS in cancer immunotherapy, emphasizing the potential of these technologies to improve treatment outcomes.